ZDNET's editorial team writes on behalf of you, our reader. Our goal is to deliver the most accurate information and the most knowledgeable advice possible in order to help you make smarter buying decisions on tech gear and a wide array of products and services. Our editors thoroughly review and fact-check every article to ensure that our content meets the highest standards. If we have made an error or published misleading information, we will correct or clarify the article. If you see inaccuracies in our content, please report the mistake via this form.
有趣的是，Infigratinib最初于2021年获批用于胆管癌，后因适应症开发策略调整而主动撤回。如今，其有望在ACH赛道迎来“第二春”。基于其疗效和口服便利性，BridgeBio在今年的JPM大会上预测，该药Infigratinib将占据ACH治疗市场50%以上的份额。，更多细节参见Line官方版本下载
。91视频对此有专业解读
Credit: Soundcore，详情可参考heLLoword翻译官方下载
This live blog is now closed.